Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$463.15 USD

463.15
947,949

+1.39 (0.30%)

Updated Sep 26, 2024 04:00 PM ET

Pre-Market: $465.00 +1.85 (0.40%) 8:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Immunome (IMNM) COVID-19 Cocktail Hold Lifted, Shares Gain

by Zacks Equity Research

Immunome (IMNM) gains as FDA lifts clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of COVID-19.

Novartis (NVS) Announces Data on Zolgensma, Acquires Coalesce

by Zacks Equity Research

Novartis (NVS) reports positive data on SMA treatment from a phase III study. It also acquires Coalesce Product Development Limited to strengthen its respiratory and complex generics business.

AbbVie (ABBV) Inks Deal for Neuropsychiatric Conditions

by Zacks Equity Research

AbbVie (ABBV) forges an alliance with Gedeon Richter to develop novel treatments for neuropsychiatric diseases. Both collaborated in the past too on the blockbuster schizophrenia drug Vraylar.

Emergent (EBS) Begins Dosing in Phase I Cyanide Poisoning Study

by Zacks Equity Research

Emergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.

Why is Viatris (VTRS) Stock Down 25% in the Year So Far?

by Zacks Equity Research

Viatris (VTRS) stock drops 25% in the year so far as investors do not seem to be impressed by the impending sale of its biosimilar business.

Moderna (MRNA) Starts Omicron-Specific Bivalent Booster Study

by Zacks Equity Research

Moderna (MRNA) administers the first dose in the phase II study of its Omicron-specific bivalent booster candidate (mRNA-1273.214). It expects to enrol 375 subjects for the same in the United States.

Denali (DNLI) Begins Frontotemporal Dementia-Granulin Study

by Zacks Equity Research

Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.

Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA

by Zacks Equity Research

Acadia (ACAD) gets an action date of Aug 4, 2022, from the FDA for its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with Alzheimer's disease psychosis.

Catalyst (CPRX) Skyrockets 110% Over a Year: Here's Why

by Zacks Equity Research

Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.

Pfizer (PFE) Begins Pediatric Study on COVID Pill Paxlovid

by Zacks Equity Research

Pfizer's (PFE) Paxlovid is the first oral antiviral pill to be studied in a pediatric clinical study.

Intellia's (NTLA) NTLA-5001 Gets FDA Orphan Drug Tag for AML

by Zacks Equity Research

Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.

Voyager (VYGR) Gains on Deal With Novartis for Gene Therapies

by Zacks Equity Research

Voyager (VYGR) stock rises on the license option agreement with Novartis to get a target-specific access to next-generation TRACER AAV capsids for gene therapy programs.

BioNTech (BNTX), Regeneron Expand Agreement for Lung Cancer Study

by Zacks Equity Research

BioNTech (BNTX) expands its strategic collaboration deal with Regeneron to evaluate the combo of BNT116 plus Libtayo for treating advanced non-small cell lung cancer.

Gilead's (GILD) Trodelvy Late-Line Breast Cancer Study Meets Goal

by Zacks Equity Research

While Gilead's (GILD) phase III study evaluating Trodelvy in late-line HR+/HER- breast cancer did achieve its primary endpoint, the lack of numerical data puts ambiguity on the significance of results.

Horizon's (HZNP) sBLA for Krystexxa Gets FDA Priority Review

by Zacks Equity Research

The FDA grants priority review to Horizon's (HZNP) sBLA for Krystexxa plus methotrexate to treat people living with uncontrolled gout. A decision is due on Jul 7, 2022.

AbbVie (ABBV) Outperforms Industry This Year So Far: What Next?

by Zacks Equity Research

AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

bluebird (BLUE) Posts Q4 Loss, Hit by Regulatory Pipeline Woes

by Zacks Equity Research

bluebird (BLUE) reports in-line fourth-quarter 2021 earnings but misses on revenues. The FDA placing clinical holds on BLUE's pipeline candidates does not augur well for the stock.

FDA Nods to Bristol Myers' (BMY) Opdivo for Additional Indication

by Zacks Equity Research

Bristol Myers' (BMY) immuno-oncology Opdivo gets FDA nod for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting in combination with platinum-doublet chemotherapy.

Sweta Killa headshot

5 Market-Beating Stocks Backed by Women Power

by Sweta Killa

Occidental Petroleum (OXY), Northrop (NOC), Hershey (HSY), Commercial Metals (CMC) and Vertex Pharma (VRTX) are among the stocks that are outperforming the market this year and are headed by female CEOs.

Merck (MRK) Outperforms Industry, What's in Store for 2022?

by Zacks Equity Research

Strong sales of key products like Keytruda and Gardasil, a significant contribution from molnupiravir and positive pipeline/regulatory developments can keep Merck's (MRK) stock afloat in 2022.

Puma Biotech (PBYI) Q4 Earnings Beat Mark, Revenues Rise Y/Y

by Zacks Equity Research

Puma Biotechnology (PBYI) beats on earnings and sales for the fourth quarter of 2021. PBYI???s shares increase in after-market trading session following the news.

Intercept (ICPT) Q4 Earnings & Sales Beat, Ocaliva in Focus

by Zacks Equity Research

Intercept (ICPT) posts a narrower loss in the fourth quarter and sales beat estimates.

Kodiak (KOD) Down More Than 80% in Past 3 Months: Here's Why

by Zacks Equity Research

Kodiak Sciences (KOD) is developing its lead candidate, KSI-301, for treating various retinal vascular diseases. The recent setback for KSI-301 has hurt the stock.

ChemoCentryx (CCXI) Q4 Earnings and Sales Miss Estimates

by Zacks Equity Research

ChemoCentryx (CCXI) posts a wider year-over-year loss in the fourth quarter and sales miss estimates. Lead drug Tavneos has been launched in the United States.

Horizon (HZNP) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Horizon's (HZNP) revenues beat estimates in the fourth quarter of 2021. Shares rise following the results.